Fizazi Karim, Albiges Laurence, Loriot Yohann, Massard Christophe
a Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, 114 rue Edouard Vaillant, 94800 Villejuif, France.
Expert Rev Anticancer Ther. 2015;15(9):1007-17. doi: 10.1586/14737140.2015.1081566.
Androgen deprivation therapy is the standard of care for patients with advanced hormone-sensitive prostate cancer. Despite an initial response, most patients progress to castration-resistant prostate cancer (CRPC). The realization that CRPC remains driven by androgen receptor (AR) signaling has formed the basis for a new generation of agents targeting the AR axis. Two of these agents, abiraterone acetate and enzalutamide, have been shown to prolong overall survival in patients with CRPC. Several other AR inhibitors are currently in development for the treatment of CRPC. The present article reviews ODM-201, a new-generation AR inhibitor with a unique molecular structure, in the treatment of CRPC. The design of an ongoing Phase III trial (ARAMIS) of ODM-201 in men with non-metastatic CRPC is also discussed, at a disease stage for which there is currently no approved treatment.
雄激素剥夺疗法是晚期激素敏感性前列腺癌患者的标准治疗方法。尽管有初始反应，但大多数患者会进展为去势抵抗性前列腺癌（CRPC）。CRPC仍然由雄激素受体（AR）信号传导驱动这一认识为新一代靶向AR轴的药物奠定了基础。其中两种药物，醋酸阿比特龙和恩杂鲁胺，已被证明可延长CRPC患者的总生存期。目前还有其他几种AR抑制剂正在开发用于治疗CRPC。本文综述了具有独特分子结构的新一代AR抑制剂ODM-201在CRPC治疗中的应用。还讨论了正在进行的ODM-201治疗非转移性CRPC男性患者的III期试验（ARAMIS）的设计，该疾病阶段目前尚无获批的治疗方法。
